Clinical trials: Thromboses, Venous
Retinitis Pigmentosa, Macula Off
Transcorneal Electrical Stimulation Therapy for Retinal Disease
Transcorneal stimulation may enable neurons to survive degeneration processes via enhanced secretion of neurotrophic substances and direct stimulation of neurons.
- Conditions
- Retinitis Pigmentosa, Macula Off, Primary Open Angle Glaucoma, Hereditary Macular Degeneration
- Trial name
- NCT00804102
- Testing
- Transcorneal Electrical Stimulation, DTL-electrode attached without energy
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Okuvision GmbH
Arterial Thromboembolism, Venous Thromboembolism
Aspiration Thrombectomy Using the Symphony or Prodigy System
The study is designed to evaluate the short-term and long-term clinical performance and safety of the Symphony and Prodigy thrombectomy systems used in endovascular procedures across the peripheral or pulmonary vasculature.
- Conditions
- Arterial Thromboembolism, Venous Thromboembolism, Pulmonary Embolism
- Trial name
- CLEAR-IT (NCT07350499)
- Testing
- Prodigy Thrombectomy System, Symphony Thrombectomy System
- Where
- 13 sites in United States
- Volunteers
- 750 people
- Sponsor
- Imperative Care, Inc.
Deep Vein Thrombosis, Coronary Artery Bypass Surgery
A Study of the Efficacy of Preventive Dosing of Fondaparinux Sodium Versus Placebo for the Prevention of Venous Thromboembolism (VTE) in Patients Undergoing Coronary Bypass Surgery Receiving Routine Mechanical Prophylaxis
This trial is a prospective, single-center Phase II randomized study to demonstrate the superior efficacy of Fondaparinux Sodium subcutaneous injections in patients undergoing CABG surgery (isolated and redo isolated) versus…
- Conditions
- Deep Vein Thrombosis, Coronary Artery Bypass Surgery, Venous Thromboembolism
- Trial name
- NCT00789399
- Testing
- Fondaparinux
- Volunteers
- 78 people
- Sponsor
- Prairie Education and Research Cooperative
Deep Vein Thrombosis Leg, DVT
ClotTriever Outcomes (CLOUT) Registry
Evaluate real world patient outcomes after treatment of acute, subacute, and chronic proximal lower extremity deep vein thrombosis (DVT) with the ClotTriever Thrombectomy System.
- Conditions
- Deep Vein Thrombosis Leg, DVT, Chronic DVT of Lower Extremity, Acute DVT of Lower Extremity
- Trial name
- CLOUT (NCT03575364)
- Testing
- ClotTriever
- Where
- 43 sites in United States
- Volunteers
- 499 people
- Sponsor
- Inari Medical
Deep Vein Thrombosis Leg, Stroke (in Patients With Atrial Fibrillation)
A Healthy Volunteer Study to Investigate the Blood Concentrations, the Effect on Blood Clotting and the Safety of Multiple Doses of DPOC-4088 Tablets in Different Doses.
A study to investigate the concentrations of a new drug DPOC-4088 in blood, and to study the effect of this drug on blood clotting parameters.
- Trial name
- NCT01647620
- Testing
- DPOC-4088
- Where
- Belgium
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Diakron Pharmaceuticals
Locally Advanced Malignant Neoplasm, Malignant Solid Tumour
A Study of ALT-836 in Combination With Gemcitabine for Locally Advanced or Metastatic Solid Tumors
This is a Phase I, open-label, multi-center, competitive enrollment and dose-escalation study of ALT-836 in combination with standard of care gemcitabine in participants who have locally advanced or metastatic solid tumors.
- Trial name
- NCT01325558
- Testing
- ALT-836 in combination with gemcitabine
- Where
- 4 sites in United States
- Volunteers
- 30 people
- Sponsor
- Altor BioScience
Venous Thrombosis Deep (Limbs), Venous Thrombosis
A Registry of the FLOWRUNNER Aspiration System for Patients With Symptomatic Venous Thrombosis
The objective of this study is to evaluate how well and how safe the FLOWRUNNER Aspiration System works for treating blood clots in the arms or legs in real-life medical settings.
- Trial name
- FAST (NCT07708376)
- Testing
- Mechanical Thrombectomy - Standard of Care procedure for venous thrombosis
- Volunteers
- 218 people
- Sponsor
- FlowPhysix, Inc.
Thrombosis, Deep Vein, Pulmonary Embolism
A Study of Adverse Events and Suspected Adverse Drug Reactions of Patients Under Treatment of Apixaban for Venous Thomboembolism (VTE) Treatment
Number, type and incidence of adverse events/suspected adverse drug reactions in patients treated with apixaban, according to therapeutic indications approved in Mexico.
- Trial name
- NCT03812835
- Sponsor
- Pfizer
Venous Thromboembolism
Efficacy of Sodium Heparin in Prophylaxis of Venous Thromboembolism in Surgical Patients
The Venous thromboembolism (VTE) disease is very frequent, mainly as complications of medical diseases and surgical procedures. It has high prevalence and can lead to severe complications such as pulmonary embolism and…
- Trial name
- NCT00912483
- Testing
- heparin sodium - Blausiegel, Heparin sodium - APP
- Volunteers
- healthy volunteers welcome
- Sponsor
- Azidus Brasil
Macular Edema, Retinal Vein Occlusion
Fluocinolone Acetonide Intravitreal Inserts for Vein Occlusion in Retina
This study will assess the safety and efficacy of FA Intravitreal Inserts in subjects with macular edema secondary to RVO.
- Trial name
- FAVOR (NCT00770770)
- Testing
- Fluocinolone Acetonide
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Alimera Sciences
Thrombosis, Venous Thrombosis
Safety and Efficacy Study of Alfimeprase in Subjects With Occluded Catheters
To evaluate the safety profile of alfimeprase as assessed by monitoring of adverse events, serious adverse events and major bleeding events for up to 120 minutes following the instillation of study drug to an occluded central…
- Conditions
- Thrombosis, Venous Thrombosis, Catheter Occlusion
- Trial name
- NCT00322270
- Testing
- Alfimeprase
- Where
- 18 sites in United States
- Sponsor
- ARCA Biopharma, Inc.
Deep-Vein Thrombosis
Oral Direct Factor Xa-inhibitor Apixaban in Patients With Acute Symptomatic Deep-vein Thrombosis-The Botticelli DVT Study
The purpose of this clinical research study is to assess efficacy and safety of 3 doses of apixaban 5 mg twice a day, 10 mg twice a day and 20 mg once daily versus conventional treatment with low molecular weight heparin or…
- Trial name
- NCT00252005
- Testing
- Apixaban
- Where
- 72 sites in United States, Australia and 9 more
- Volunteers
- 520 people
- Sponsor
- Bristol-Myers Squibb
Venous Thromboembolism, Deep Vein Thrombosis (DVT)
Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study).
Evaluation of heparin/edoxaban tosylate (DU176b) versus heparin/warfarin in preventing recurrence of blood clots in patients with acute symptomatic deep-vein blood clots in the legs and/or blood clots in the lungs.
- Conditions
- Venous Thromboembolism, Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Thromboembolism
- Trial name
- NCT00986154
- Testing
- edoxaban tosylate(DU-176b), low molecular weight heparin/unfractionated heparin, warfarin
- Where
- 454 sites in United States, Argentina and 36 more
- Volunteers
- 8,292 people
- Sponsor
- Daiichi Sankyo
Retinal Vein Occlusion
Pegaptanib Sodium Compared to Sham Injection in Patients With Recent Vision Loss Due to Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO)
Eyetech Pharmaceuticals Inc. and Pfizer, Inc. are studying an investigational drug, MacugenTM, for the possible treatment of CRVO. An investigational drug is one that has not been approved by the U.S.
- Trial name
- NCT00088283
- Testing
- pegaptanib sodium
- Where
- 35 sites in United States
- Volunteers
- 90 people
- Sponsor
- Eyetech Pharmaceuticals
Venous Thromboembolism
Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Major Abdominal Surgery
The primary objective is to compare the efficacy and safety of once daily (q.d.) subcutaneous (s.c.) injections of Semuloparin sodium (AVE5026) with q.d. s.c.
- Trial name
- SAVE-ABDO (NCT00679588)
- Testing
- Semuloparin Sodium, Enoxaparin sodium
- Where
- 270 sites in United States, Argentina and 37 more
- Volunteers
- 4,413 people
- Sponsor
- Sanofi
Venous Thromboembolism
An Observational Study On The Safety And Tolerability Of Prolonged Thrombosis Prophylaxis With Fragmin®
The objective of this study is to observe the safety, tolerability, and compliance in the use of Fragmin® for prolonged thromboprophylaxis in post-surgery high-risk orthopedic patients.
- Trial name
- NCT01046903
- Testing
- Fragmin® (Dalteparin Sodium)
- Volunteers
- 503 people
- Sponsor
- Pfizer
Chronic Venous Thrombosis, Venous Thrombosis Upper Extremity
Surfacer System to Facilitate Access in Venous Occlusions
Prospective, single-arm, multicentre, international Registry of the Surfacer System for the treatment of patients with limited or diminishing upper body venous access or pathology impeding standard access methods.The purpose of…
- Conditions
- Chronic Venous Thrombosis, Venous Thrombosis Upper Extremity, Venous Thrombosis Upper Extremity Superficial Veins
- Trial name
- SAVE (NCT02875899)
- Where
- 4 sites in Austria, Germany and 1 more
- Volunteers
- 30 people
- Sponsor
- Merit Medical Systems, Inc.
Venous Thromboembolism (VTE), Deep Vein Thrombosis (DVT)
Cancer Venous Thromboembolism (VTE)
The primary objective is to demonstrate the non-inferiority of edoxaban (preceded by a short course of LMWH) compared with dalteparin for the prevention of the combined outcome of recurrent venous thromboembolism (VTE) or major…
- Conditions
- Venous Thromboembolism (VTE), Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Cancer
- Trial name
- NCT02073682
- Testing
- Edoxaban, Dalteparin, Low molecular weight heparin
- Where
- 9 sites in United States, Belgium and 4 more
- Volunteers
- 1,046 people
- Sponsor
- Daiichi Sankyo
Retinal Vein Occlusion
Safety and Proof of Concept Study of ANXV (Annexin A5) in Patients With Retinal Vein Occlusion
Open-label, dose ascending safety, tolerability, and proof of concept study to evaluate the use of ANXV (human recombinant Annexin A5) in the treatment of subjects with recently diagnosed Retinal Vein Occlusion.
- Trial name
- NCT05532735
- Testing
- ANXV
- Where
- 7 sites in United States
- Volunteers
- 16 people
- Sponsor
- Annexin Pharmaceuticals AB
Venous Thromboembolism
An Oral, Direct Factor Xa Inhibitor, BAY59-7939, for Prophylaxis Against Venous Thromboembolism After Total Knee Replacement: a Dose-Ranging Study
The study drug, BAY59-7939, is a new drug currently being tested in the prevention of VTE. It directly inhibits factor Xa, a blood component in the pathway which leads to coagulation (clotting of blood cells).
- Trial name
- NCT00402467
- Testing
- Rivaroxaban (BAY59-7939), Rivaroxaban, (BAY59-7939), Enoxaparine
- Where
- 36 sites in United States, Canada
- Volunteers
- 613 people
- Sponsor
- Bayer